Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Peru

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

- PMLiVE

Takeda’s Entyvio recommended by NICE for bowel disease

But must supply the drug at a discounted rate to the NHS

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

Takeda grows in Turkey with Neutec subsidiary acquisition

Will acquire Toplam Kalite for up to 300m Turkish lira

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

- PMLiVE

Takeda’s ‘oral Velcade’ clears first phase III hurdle

Ixazomib shows early stage promise for myeloma

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

Takeda enlists GE’s aid to tackle liver fibrosis epidemic

Non-alcoholic liver disease has doubled in the last 20 years

- PMLiVE

Takeda launches mobile app for heartburn patients

Food4GERD app includes symptom tracker and ingredient check functions

- PMLiVE

US judge cuts billions from Takeda/Lilly Actos payment

Court rules that companies must now pay damages of $36.8m rather than $9bn

- PMLiVE

Takeda’s obesity drug Contrave launches in US

Clears cardiovascular safety hurdle to be third new weight-loss drug in recent months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links